Guanfacine Tablet, Extended Release
Product Images NDC 63304-924

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 63304-924). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Guanfacine 4 mg

Label for Guanfacine Extended-Release Tablets, USP 4 mg by Sun Pharmaceutical Industries, Inc. The label specifies a bottle containing 100 tablets. It includes warnings that tablets should not be crushed, chewed, or broken before swallowing, and provides storage instructions and details for patient information access.*

FDA Label Image

Guanfacine 1 mg

Label for Guanfacine Extended-Release Tablets, USP 1 mg by Sun Pharmaceutical Industries, Inc. The label indicates a bottle containing 100 tablets, with a warning that tablets should not be crushed, chewed, or broken before swallowing. It also includes NDC 63304-924-01 and the manufacturer's details.*

FDA Label Image

Guanfacine 2 mg

Label for Guanfacine Extended-Release Tablets, USP 2 mg, oral dosage form. The label states it contains 100 tablets with a caution that tablets should not be crushed, chewed, or broken before swallowing. Manufactured by Ohm Laboratories, Inc. and distributed by Sun Pharmaceutical Industries, Inc. The label includes an NDC number 63304-925-01 and storage instructions.*

FDA Label Image

Guanfacine 3 mg

Label for Guanfacine Extended-Release Tablets, USP 3 mg, oral dosage form by Sun Pharmaceutical Industries, Inc. The label states the tablets should not be crushed, chewed, or broken before swallowing. It indicates 100 tablets per container, Rx only, with storage and dosing instructions and barcodes visible.*

FDA Label Image

Figure1 (Image 05)

A pharmacokinetic graph showing Guanfacine plasma concentration (ng/mL) over 24 hours. It compares guanfacine extended-release tablets 1 mg once daily (squares) and Tenex 1 mg once daily (triangles). The y-axis represents plasma concentration, and the x-axis represents time in hours.*

FDA Label Image

Figure 2 (Image 06)

A pharmacokinetic (PK) chart showing fold changes and 90% confidence intervals (CI) for Cmax and AUC values due to various CYP3A4/5 inhibitors (Ketoconazole, Fluconazole) and inducers (Rifampin, Efavirenz), as well as Oral Methylphenidate and Lisdexamfetamine Dimesylate, based on human data and computer simulations. The x-axis represents fold change relative to the reference.*

FDA Label Image

Figure 3 (Image 07)

A horizontal forest plot chart showing the pharmacokinetic fold change and 90% confidence intervals for Cmax and AUC parameters of Guanfacine when interacting with Oral Methylphenidate and Lisdexamfetamine Dimesylate. The x-axis represents fold change relative to reference, ranging from 0.0 to 2.0.*

FDA Label Image

Spl Guanfacine Figure 4

A Kaplan-Meier survival curve chart showing treatment failure percentage over time in days. Two lines compare Placebo and SPD503 groups, with treatment failure increasing over the 200-day period. The y-axis represents treatment failure percentage and the x-axis time to treatment failure in days.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of guanfacine hydrochloride, showing its molecular connections including chlorine atoms, an amide group, and an amino group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.